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(the only available biomarker of muscle glycogenosis type II) 
and brain MRI if there are symptoms suggestive of CNS in-
volvement.
In conclusion, being available the ERT therapy, it is really 
important to diagnose Pompe disease as soon as possible to 
avoid respiratory and skeletal muscle degeneration. 
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The authorisation to treat patients by ERT has to be given 
by Centres specialized in rare diseases. Every Centre must as-
sess the diagnosis of Pompe disease with absolute certainty be-
fore starting treatment. 
In 2008, a group of Italian Pompe disease experts reviewed, 
from a multidisciplinary point of view, the current practices in 
diagnosis, management and treatment of Pompe disease (2). 
The main criteria for starting ERT included: 1) confirmed di-
agnosis; 2) symptoms and clinical signs of muscle weakness 
and or respiratory insufficiency; 3) in cases of asymptomatic 
hyperckemia, a 6-months follow up was suggested in an attempt 
to monitor clinically relevant changes leading to treatment. 
The standard protocol mainly includes evaluation of mus-
cle strength, respiratory assessment and skeletal muscle MRI 
that has been applied to 74 patients treated with ERT coming 
from 18 different Italian Centres, recently described by Angelini 
et al. (3). 
Nowadays, general recommendations includes monitoring 
of limb muscles and respiratory functions every 6 months using 
timed tests and functional scales. Muscle MRI may constitute 
an important tool to check the progression of intramuscular fat 
replacement in the patients (4). 
Respiratory function should include at least assessment of 
upright and supine FVC. Other important aspects of the disease 
to be considered are the cardiac function (ECG once a year) as 
well as antiRhGAA antibodies (every 3 months) levels, Glc4 